Pre-made Mepolizumab biosimilar ( Whole mAb, anti-IL5 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-341
Anti-IL5 therapeutic antibody (Pre-made Mepolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL5 therapeutic antibody (Pre-made Mepolizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||GlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases|
|Conditions Approved||Asthma;Churg-Strauss syndrome;Hypereosinophilic syndrome|
|Conditions Active||Chronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Eosinophilic oesophagitis|
|Conditions Discontinued||Atopic dermatitis|